Arecor
- Company typePublic
- Founded2007
- HeadquartersLittle Chesterford, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
Arecor firmographics
Firmographics- Name
- Arecor
- Legal name
- Arecor Therapeutics plc
- Website
- https://arecor.com
- Company type
- Public
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Arecor industry classification
Industry- Product category
- Biopharmaceutical Formulation Technology
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)
- akta.pro secondary industry
- Pen Injectors (Insulin/GLP-1/Other Pens) (HLAHAIAC)
Keywords
Where Arecor is headquartered
LocationHeadquarters
- HQ city
- Little Chesterford
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Arecor business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Technology Licensing: Partners pay technology development fees and upon completion have the option to enter into license agreements for rights to access IP and further develop and commercialise novel formulations. Licenses typically involve milestone and royalty payments.
- Royalty Rights Monetization: Sale of global royalty rights to AT220 and all potential milestone and technology access fees related to AT292 to Ligand Pharmaceuticals for $11 million in September 2025. Ongoing milestone payments from Ligand.
- Co-development Agreements: Revenue generating from co-development partnerships such as agreement with Sequel Med Tech for AT278 development. Partners share development costs and provide upfront payments.
- Existing License Revenue: Revenue from existing partnerships including Sanofi programme SAR447437 (AT292), biosimilar product AT220 under worldwide licensing agreement, and AT351 under exclusive milestone and royalty-bearing licensing agreement.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Arecor product offering
Product offeringCore offering
Arecor is a clinical-stage biopharmaceutical company that develops superior therapeutics for diabetes, obesity and other cardiometabolic diseases using its proprietary Arestat® drug formulation technology platform. It licenses Arestat to leading pharmaceutical and medtech partners in exchange for development fees, milestone payments and royalties, while also advancing its own proprietary pipeline including AT278 (ultra-concentrated ultra-rapid-acting insulin for AID systems) and an oral GLP-1 receptor agonist programme.
Product overview
Arecor is a clinical-stage biotech company developing superior therapeutics for diabetes, obesity, and other cardiometabolic diseases using its proprietary Arestat technology platform. The company's portfolio includes proprietary products (AT278, an ultra-concentrated ultra-rapid-acting insulin for AID systems, and an oral GLP-1 receptor agonist programme) alongside partnered products (AT220 biosimilar, AT292/SAR447537 licensed to Sanofi, and AT351). Arecor operates as a platform company, licensing its Arestat technology to pharmaceutical partners while advancing its own pipeline.
Differentiator
Problem solved
Functional benefit
Products and services
- AT278 Best-in-class, ultra-concentrated (500U/mL), ultra-rapid-acting insulin designed to transform Automated Insulin Delivery (AID) systems. The only insulin suitable for AID pump use in high insulin users, enabling next-generation miniaturised, longer-wear pumps for Type 1 and Type 2 diabetes patients. Co-developed with Sequel Med Tech for use in the twiist AID system.
- AT220 Arestat-enhanced biosimilar product under a worldwide licensing agreement, generating licensing and royalty revenue for Arecor; global royalty rights were subsequently sold to Ligand Pharmaceuticals for $11 million in September 2025.
- AT292 (SAR447537) Sanofi's programme (formerly INBRX-101) incorporating Arestat® technology under a revenue-generating licence. Generates milestone and royalty payments for Arecor from Sanofi's development and commercialisation.
- AT351 Arestat-enhanced product under an exclusive milestone and royalty-bearing licensing agreement with a subsidiary of one of the world's largest independent chemicals marketing companies, providing an additional technology-licensing revenue stream.
- Oral GLP-1 Receptor Agonist (Semaglutide) Programme Novel oral delivery platform for peptides, initially targeting an oral GLP-1 receptor agonist (semaglutide) with significantly improved bioavailability versus current marketed products (Rybelsus achieves less than 1% bioavailability). Addresses the multi-billion dollar obesity and cardiometabolic disease markets.
- Arestat® Technology Platform Proprietary formulation and drug delivery technology platform licensed to pharmaceutical and biotech partners to develop products with enhanced properties including improved stability, extended shelf-life, cold-chain elimination, high-concentration low-viscosity subcutaneous formulations, ready-to-use and ready-to-administer IV formats, lyophilised-to-liquid switches, and controlled pharmacokinetic / pharmacodynamic profiles.
Quantifiable outcome
- AT278 shows best-in-class profile compared to best gold-standard insulins currently available
- +3 more outcomes
Companies that use Arecor
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles2 records
Arecor technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Arecor partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered strategic, core and minor.
- Tandem Diabetes CarestrategicIndustry partner in University of Virginia $4.7M AI-powered diabetes management project. Tandem provides in-kind contributions totaling $800,000 alongside $3.9M grant from Breakthrough T1D and Helmsley Charitable Trust. Collaboration focuses on next-generation fully closed-loop insulin delivery systems combining adaptive ML algorithms with ultra-rapid-acting insulin.
- Sequel Med TechcoreCo-development agreement with US insulin pump developer for AT278, an ultra-concentrated insulin, to undertake preparatory work for Phase 2 clinical trial for combined AT278/Insulin Pump programme. AT278 will be used in Sequel's twiist AID system which precisely measures each dose of insulin.
- Skye BioSciencestrategicCollaboration partnership announced in 2025 focused on undisclosed therapeutic development. Demonstrates growing partnership pipeline and value of Arecor's technology platform.
- SanofistrategicSanofi's programme SAR447537 (formerly INBRX-101, now AT292) incorporates Arestat technology under a revenue-generating license. Arecor receives milestone and royalty payments from this partnership.
- Tetris Pharma LtdminorAcquired by Arecor Therapeutics in August 2022 (contingent upon successful capital offering). Tetris was Xeris' commercialization partner for Ogluo glucagon rescue pen in UK, EEA, and Switzerland. Business ceased operations in 2025.
Scale indicators8 records
Recent moves7 records
Expansion highlights5 records
Arecor competitors and assessment
Company assessmentDirect peers
- Halozyme Therapeutics: Halozyme operates the ENHANZE drug delivery platform, licensing it to major pharmaceutical companies for subcutaneous formulation of biologics — closely mirroring Arecor's Arestat platform licensing model with Big Pharma partners.
- Adocia: Adocia develops innovative formulations of insulin and other peptides for diabetes, including ultra-rapid-acting insulin analogues using its BioChaperone platform — directly competitive with Arecor's AT278 in the ultra-rapid insulin space.
- MannKind Corporation: MannKind develops Technosphere drug delivery technology and commercialized Afrezza inhaled insulin — a small-cap diabetes specialist with a proprietary delivery platform addressing similar unmet needs to Arecor's Arestat platform.
- Xeris Biopharma: Xeris develops ready-to-use, room-temperature-stable injectable formulations (including Ogluo glucagon, which Arecor previously commercialized through Tetris) — a direct peer in formulation technology and diabetes/endocrine therapies.
- Zealand Pharma: Zealand Pharma is a clinical-stage peptide therapeutics company with platform technology for modified peptides, including programmes in diabetes/obesity — comparable to Arecor's peptide-focused, platform-driven development model.
Emerging players
- Crinetics Pharmaceuticals: Crinetics is an emerging clinical-stage biotech developing peptide therapeutics for endocrine diseases — a peer in modality and therapeutic focus, though focused on rare endocrine conditions rather than diabetes/obesity.
- Tandem Diabetes Care: Tandem is a leading US insulin pump and AID system developer and an industry partner with Arecor in the University of Virginia AI-powered diabetes management project — a peer and ecosystem partner in the AID system market that AT278 is designed to serve.
Broad incumbents
- Eli Lilly: Eli Lilly is a global pharmaceutical incumbent with dominant diabetes (Humalog, Lyumjev) and obesity (Mounjaro/Zepbound) franchises — sets the competitive bar in Arecor's target therapeutic areas and has deep formulation and pump-partner relationships.
- Novo Nordisk: Novo Nordisk is the global leader in diabetes care and GLP-1 receptor agonists (Rybelsus is the established oral semaglutide) — represents both the dominant competitor and the standard Arecor must surpass with its oral peptide platform.
- Sanofi: Sanofi is both Arecor's licensing partner (AT292/SAR447537) and a broad incumbent in diabetes (Lantus, Toujeo) and cardiometabolic disease — comparable as a potential acquirer and as a benchmark for the kind of large-pharma relationships Arecor is building.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Arecor social profiles
Digital presenceArecor financial estimates
Financial estimateRevenue estimate
Valuation estimate
Arecor leadership team
Management profileNumber of profiles
Profiles8 records
Arecor subsidiaries and ownership
Company hierarchySubsidiaries2 records
Arecor funding detail
Funding detailFunding overview
Funding rounds12 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Arecor M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Arecor
What does Arecor do?
Arecor is a clinical-stage biopharmaceutical company that develops superior therapeutics for diabetes, obesity and other cardiometabolic diseases using its proprietary Arestat® drug formulation technology platform. It licenses Arestat to leading pharmaceutical and medtech partners in exchange for development fees, milestone payments and royalties, while also advancing its own proprietary pipeline including AT278 (ultra-concentrated ultra-rapid-acting insulin for AID systems) and an oral GLP-1 receptor agonist programme.
Is Arecor a public or private company?
Arecor is a public company. It is classified as public and is currently operating.
When was Arecor founded?
Arecor was founded in 2007. It employs 11 to 50 people.
Where is Arecor based?
Arecor is headquartered in Little Chesterford, United Kingdom, in the Europe region.
How does Arecor make money?
Four revenue lines are on record. Technology Licensing is the primary driver. The others are royalty Rights Monetization, co-development Agreements and existing License Revenue.
Who are Arecor's main competitors?
Direct peers on record are Halozyme Therapeutics, Adocia, MannKind Corporation, Xeris Biopharma and Zealand Pharma. Emerging players are Crinetics Pharmaceuticals and Tandem Diabetes Care. Broad incumbents are Eli Lilly, Novo Nordisk and Sanofi.
Does Arecor have an API?
No public API is recorded for Arecor.
What industry is Arecor in?
Arecor's product category is Biopharmaceutical Formulation Technology. Its primary akta.pro industry code is HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support, with a secondary code of HLAHAIAC, Pen Injectors (Insulin/GLP-1/Other Pens). Its NAICS code is 541714 and its SIC code is 2834.